Velodyne Lidar Showcases Full Stack Vision Solutions for Robotics, Industrial and Trucking at XPONENTIAL 2022
20.4.2022 13:48:00 EEST | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) will demonstrate its innovative lidar sensors and software at XPONENTIAL 2022 in Orlando from April 26 to 28 – booth #2149. Velodyne will highlight how its lidar technology powers autonomous solutions in robotics, industrial, trucking and more that are advancing safety, sustainability, efficiency and equity on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005427/en/
Velodyne Lidar will demonstrate its innovative lidar sensors and software at XPONENTIAL 2022 – booth #2149. Velodyne will display its cutting-edge Velarray M1600, Puck and Ultra Puck sensors that provide companies the performance, reliability and scalability needed in a wide range of applications. It will also show the Vella Development Kit which allows customers to plug in Velodyne’s lidar with an off-the-shelf library of perception software functions. (Photo: Velodyne Lidar)
Supply chain capacity issues, roadway congestion, safety concerns and labor shortages are driving autonomous system deployments. Velodyne delivers the lidar sensors and software that solve customers’ system-level challenges to develop full-stack autonomous solutions and accelerate their time to market.
At XPONENTIAL, Velodyne will display its cutting-edge Velarray M1600, Puck and Ultra Puck sensors that provide companies the performance, reliability and scalability needed in a wide range of applications. It will also show the Vella Development Kit which allows customers to plug in Velodyne’s lidar with an off-the-shelf library of perception software functions, fast tracking their solution development for ever-evolving applications.
Attendees can immerse themselves in an augmented reality (AR) demonstration to experience how Velodyne’s M1600 sensors perceive the world. Additionally, Velodyne will be joined by Clearpath Robotics, which will showcase its Husky Unmanned Ground Vehicle, powered by Velodyne’s Puck, which is engineered to thrive in harsh outdoor, all-terrain environments.
“XPONENTIAL attendees can see how Velodyne’s sensor and software portfolio is shaping the wave of autonomous solution commercialization taking place in the industrial, robotics and automotive sectors,” said Sally Frykman, Chief Marketing Officer, Velodyne Lidar. “Now more than ever before, we live in a world in motion. To keep pace, industries are deploying smarter technology. Companies can rely on our lidar-based solutions to help their automated systems transform lives and make communities safer.”
How Lidar Solutions Advance Roadway and Supply Chain Efficiency
At the XPONENTIAL conference, Christina Aizcorbe, Velodyne’s Vice President of Government Affairs, will speak on a panel on the commercialization of automated trucking. Mrs. Aizcorbe will discuss how current automated trucking deployments are not just proving out a theoretical concept. They are bringing critical and credible real-world data which will support expansion, making the benefits that will come with commercialization very real to U.S. consumers. Innovation in freight and cargo movement will also spur economic growth well beyond trucking.
The session, called “What Does the Commercialization of Automated Trucking Look Like? – Part 2,” takes place on April 25 from 2:50 p.m. to 3:45 p.m. EDT at Room S330A/B.
“We are seeing rapid growth in automation across other parts of the supply chain, like the use of the same advanced sensing technologies used in automated driving systems to improve efficiency in warehouse and logistics operations, and port automation. Lidar technology is essential to ensuring sensor redundancy and around the clock safe performance of these systems,” said Mrs. Aizcorbe.
To schedule an XPONENTIAL meeting at the Velodyne booth, contact Velodyne Sales: 669.275.2526, sales@velodyne.com.
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality, and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005427/en/
Contact information
Velodyne Investor Relations
InvestorRelations@velodyne.com
Media
Codeword
Liv Allen
velodyne@codewordagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
